Chemicals giant Bayer rules out break-up 'for now' after huge loss / Photo: Ina FASSBENDER - AFP/File
-
Mutual fund returns show shifting leaders across market-cap categories
-
BHEL wins Adani Power projects valued at up to ₹28,000 crore
-
IndiGo holds talks with Embraer over potential order for 100 aircraft
-
India seeks threefold increase in coal stocks to prevent summer power shortages
-
Indian companies report mixed second-quarter results on November 4
-
Indus Towers expands solar-powered network to 50,000 telecom sites
-
KKR secures Indian regulator approval for Gentari Renewables investment
-
Equitas Small Finance Bank rebounds after naming interim chief executive
-
Bharti Airtel revenue expected to grow at double-digit pace in second quarter
-
Titan quarterly profit seen rising as jewellery business drives growth
-
Indian crude-sensitive shares gain after 13% oil-price decline
-
Kuwait finance minister holds economic cooperation talks at COMCEC
-
Stocks and dollar fall as Democratic election gains reshape markets
-
Kuwait marks key events and anniversaries from national history
-
Qatar Tourism joins Pacific Asia Travel Association at London travel market
-
Qatar media bodies discuss support for humanitarian initiatives
Chemicals giant Bayer rules out break-up 'for now' after huge loss
German chemicals giant Bayer vowed Tuesday to "urgently" address key challenges after plunging deep into the red in 2023, weighed down by woes related to its glyphosate-based weedkillers.
But CEO Bill Anderson, hired last year to help steer the troubled group in a new direction, ruled out any imminent break-up of the company -- despite mounting pressure from activist investors.
Bayer swung to a 2.9-billion-euro loss ($3.1 billion) in 2023 after booking a net profit of 4.15 billion euros a year earlier, it said in a statement.
Sales fell by six percent to 47.6 billion euros, partly because of "significantly" lower prices for glyphosate-based herbicides in the group's crop science division.
Earnings were also dragged down by heavy impairment losses in the same division.
Sales of prescription medicines in the pharmaceuticals division were flat, while the consumer health unit saw an uptick in part thanks to higher demand for dermatology products.
Anderson said Bayer faced "four challenges that urgently must be addressed."
Bayer, maker of Aspirin, has to strengthen its pharmaceuticals pipeline, he said, referring to the need to launch new products to compensate for the expiration of patents on several blockbuster drugs in the coming years.
The group also needs to address massive litigation issues linked to the Roundup weedkiller, Anderson said, a problem Bayer inherited in the 2018 takeover of US firm Monsanto.
Bayer has faced a wave of lawsuits in the United States over claims Roundup, which contains the active ingredient glyphosate, causes cancer. Bayer denies the claim but has spent billions of euros on legal costs in recent years.
The group's high debt levels and a hierarchical bureaucracy that "blocks progress" were also key issues that need tackling, Anderson added.
But he pushed back against pressure from activist investors who want to split up the company and spin off at least one branch to generate cash.
On the question of a possible break-up of the group, "our answer is 'not now' –- and this shouldn't be misunderstood as 'never'," said Anderson.
"Our priority is on tackling our challenges," he added.
Bayer, which has already warned there would be "significant" job cuts to help turn around the group's fortunes, said it aimed to make savings of two billion euros a year from 2026.
Looking ahead, the group expects full-year sales to come in at 47 billion to 49 billion euros in 2024, while earnings are expected to decline again.
P.Gonzales--CPN